Skip to main content

Finance & Markets

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Key PointsIt's a cancer medication with immense potential.

nasdaq.com ·2h ago

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? fool.com

Read the original at nasdaq.com →

More in Finance & Markets

Better Buy: XRP (Ripple) vs. Bitcoin

Between Bitcoin and XRP, the simpler bet wins: Bitcoin's case rests on a hard-coded 21 million coin cap, while XRP's depends on Ripple converting business growth into token demand -- and Ripple's own…

2h ago ·fool.com

Alnylam Pharmaceuticals stock falls on silencer drug concerns

Alnylam stock drops 6% following AstraZeneca's trial results
Phase 3 trial shows no improvement in ATTR-CM patients
Silencer drug market faces competitive pressure

2h ago ·investing.com

Investors at least $4.7 billion underwater across Trump crypto ventures, Public Citizen says

Investors are $4.7 billion underwater across Trump crypto ventures while Trump earned $1.4 billion, Public Citizen reported.

2h ago ·theblock.co

Marvell slides as guidance disappoints; Wall Street wants more details on Google revenue

2h ago ·seekingalpha.com

Warsh Doesn’t Run Much Risk of Losing Control of Bonds, Says Academy’s Tchir

Peter Tchir, head of macro strategy at Academy Securities, says of the US Treasury market, “I don’t think this is a bond vigilante thing, I think it’s supply and demand,” ahead of Federal Reserve…

2h ago ·bloomberg.com

At a glance: stocks gapping up premarket

2h ago ·seekingalpha.com

More from Friday 28 August →